ODT - Odonate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.10
+0.97 (+3.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close32.13
Open32.43
Bid32.99 x 800
Ask33.14 x 3100
Day's Range31.44 - 33.84
52 Week Range11.54 - 43.75
Volume95,162
Avg. Volume104,706
Market Cap1.062B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019

    Odonate Therapeutics, Inc. , a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2019.

  • Business Wire

    Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer. The Company expects to report top-line results from CONTESSA in the third quarter of 2020. Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer.

  • Business Wire

    Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock, offered at a price of $26.00 per share. In addition, Odonate has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock on the same terms and conditions. All shares of common stock sold in the offering are being sold by Odonate.

  • Business Wire

    Odonate Therapeutics Announces Public Offering of Shares of Common Stock

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering of approximately $100 million of shares of its common stock. In addition, Odonate has granted the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock. All of the shares of common stock to be sold in the underwritten public offering are being offered by Odonate.

  • Business Wire

    Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue with No Modifications following Planned Interim Efficacy Futility Analysis

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that the IDMC for CONTESSA, Odonate’s Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer, recommended that the study continue with no modifications following a planned interim efficacy futility analysis. The interim efficacy futility analysis was based on a pre-specified analysis of the first approximate 100 progression-free survival (PFS) events that occurred in the study. PFS is the primary endpoint of CONTESSA.

  • Business Wire

    Odonate Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, at 2:00 p.m. Eastern Time. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer.

  • Business Wire

    Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019

    Odonate Therapeutics, Inc. , a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2019.

  • Business Wire

    Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today presented results of preclinical studies of tesetaxel, Odonate’s investigational, orally administered taxane, at the American Association for Cancer Research (AACR) Annual Meeting 2019. These preclinical results indicate that, following oral administration, tesetaxel achieves brain concentrations that exceed concentrations required for tumor killing for a sustained period of time. “The development of effective treatment options for patients with brain metastases remains an enormous unmet medical need”, said Nancy Lin, M.D., Associate Chief of Breast Oncology, Susan F. Smith Center for Women’s Cancers, and Director of the EMBRACE Metastatic Breast Cancer Program, Dana-Farber Cancer Institute.

  • Business Wire

    Odonate Therapeutics Initiates CONTESSA TRIO

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of CONTESSA TRIO, a multi-cohort, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational, orally administered taxane. Nivolumab and pembrolizumab (PD-1 inhibitors) and atezolizumab (a PD-L1 inhibitor) are IO agents approved for the treatment of multiple types of cancer.

  • Business Wire

    Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. Eastern Time. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer.

  • Business Wire

    Odonate Therapeutics Announces Initiation of CONTESSA 2, a Phase 2 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA 2, a multinational, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational, orally administered taxane, in patients with locally advanced or metastatic breast cancer (LA/MBC) who have not previously received a taxane. CONTESSA 2 will investigate the combination of tesetaxel plus a reduced dose of capecitabine in approximately 125 patients with human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive disease.

  • Business Wire

    Odonate Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the acceptance for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 of an abstract describing results of preclinical studies of tesetaxel, Odonate’s investigational, orally administered taxane. This is in contrast to paclitaxel and docetaxel, the most commonly prescribed taxanes, which do not substantially cross the blood-brain barrier.

  • Business Wire

    Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018

    Odonate Therapeutics, Inc. , a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2018.

  • GlobeNewswire

    Detailed Research: Economic Perspectives on Omnicom Group, Venator Materials, Leidos, International Flavors & Fragrances, Odonate Therapeutics, and Aqua America — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.